of, or reduction in, the inhibitory effects of CD5 is associated with
RAG re-expression in B cells in patients with SLE and these may
synergize to induce autoantibody production.
In conclusion, the ﬁnding that IL-6 activates CD5-E1B tran-
scription is relevant for understanding mechanism of action and
therapeutic beneﬁts of anti-IL-6. Thus, treatment of patients with
SLE with anti-IL-6R mAb could inhibit autoreactive B cell expan-
sion by restoring DNA methylation and cell cycle progression. In
addition, the data provide further evidence for the pivotal role of
CD5 in maintaining anergy in autoreactive B cells.
We are grateful to the Conseil Re´gional de Bretagne, the Conseil Ge´ne´ral
du Finiste`re, the College Doctoral International, and the Universite´ Europ-
e´enne de Bretagne for support. Thanks are also due to Cindy Se´ne´ and
Simone Forest for excellent secretarial assistance.
The authors have no ﬁnancial conﬂict of interest.
1. Rahman, A., and D. A. Isenberg. 2008. Systemic lupus erythematosus. N. Engl.
J. Med. 358: 929–939.
2. Renaudineau, Y., P. O. Pers, B. Bendaoud, C. Jamin, and P. Youinou. 2004.
Dysfunctional B cells in SLE. Autoimmun. Rev. 3: 516 –523.
3. Leandro, M. J., J. C. Edwards, G. Cambridge, M. R. Ehrenstein, and
D. A. Isenberg. 2002. An open study of B lymphocyte depletion in systemic lupus
erythematosus. Arthritis Rheum. 46: 2673–2677.
4. Illei, G., C. Yarboro, Y. Shirota, E. Tackey, L. Lapteva, and T. Fleisher. 2006.
Tocilizumab (humanized anti IL-6 receptor monoclonal antibody) in patients with
systemic lupus erythematosus (SLE): safety, tolerability and preliminary efﬁcacy.
Arthritis Rheum. 54 (Suppl): 4043 (Abstract).
5. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with
CTLA4Ig. Science 265: 1225–1227.
6. Hom, G., R. R. Graham, B. Modrek, K. E. Taylor, W. Ortmann, S. Garnier,
A. T. Lee, S. A. Chung, R. C. Ferreira, P. V. Pant, et al. 2008. Association of
systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl.
J. Med. 358: 900–909.
7. Ballestar, E., M. Esteller, and B. C. Richardson. 2006. The epigenetic face of
systemic lupus erythematosus. J. Immunol. 176: 7143–7147.
8. Zhu, B., Y. Zheng, H. Angliker, S. Schwarz, S. Thiry, M. Siegmann, and
J. P. Jost. 2000. 5-Methylcytosine DNA glycosylase activity is also present in the
human MBD4 (G/T mismatch glycosylase) and in a related avian sequence. Nu-
cleic Acids Res. 28: 4157– 4165.
9. Hendrich, B., and A. Bird. 1998. Identiﬁcation and characterization of a family
of mammalian methyl-CpG binding proteins. Mol. Cell Biol. 18: 6538 –6547.
10. Schwab, J., and H. Illges. 2001. Regulation of CD21 expression by DNA meth-
ylation and histone acetylation. Int. Immunol. 13: 705–710.
11. Lu, Q., A. Wu, L. Tesmer, D. Ray, N. Yousif, and B. Richardson. 2007. De-
methylation of CD40LG on the inactive X in T cells from women with lupus.
J. Immunol. 179: 6352–6358.
12. Piotrowski, P. C., S. Duriagin, and P. P. Jagodzinski. 2005. Expression of HERV
clone 4-1 may correlate with blood plasma concentration of anti-U1 RNP and
anti-Sm nuclear antibodies. Clin. Rheumatol. 24: 620 – 624.
13. Deng, C., M. J. Kaplan, J. Yang, D. Ray, Z. Zhang, W. J. McCune, S. M. Hanash,
and B. C. Richardson. 2001. Decreased ras-mitogen-activated protein kinase sig-
naling may cause DNA hypomethylation in T lymphocytes from lupus patients.
Arthritis Rheum. 44: 397–407.
14. Hippen, K. L., L. E. Tze, and T. W. Behrens. 2000. CD5 maintains tolerance in
anergic B cells. J. Exp. Med. 191: 883– 890.
15. Jamin, C., G. Magadur, A. Lamour, L. MacKenzie, P. M. Lydyard, P. Katsikis,
and P. Youinou. 1992. Cell-free CD5 in patients with rheumatic diseases. Im-
munol. Lett. 31: 79– 84.
16. Lu, X., R. C. Axtell, J. F. Collawn, A. Gilson, L. B. Justement, and C. Raman.
2002. AP2 adaptor complex-dependent internalization of CD5: differential reg-
ulation in T and B cells. J. Immunol. 168: 5612–5620.
17. Renaudineau, Y., S. Hillion, A. Saraux, R. A. Mageed, and P. Youinou. 2005. An
alternative exon 1 of the CD5 gene regulates CD5 expression in human B lym-
phocyte. Blood 106: 2781–2789.
18. Renaudineau, Y., S. Vallet, C. Le Dantec, S. Hillion, A. Saraux, and P. Youinou.
2005. Characterization of the human CD5 endogenous retrovirus-E in B lym-
phocytes. Gene Immun. 6: 663– 671.
19. Garaud, S., C. Le Dantec, C. Berthou, P. M. Lydyard, P. Youinou, and
Y. Renaudineau. 2008. Selection of the alternative exon 1 from the cd5 gene
down-regulates membrane level of the protein in B lymphocytes. J. Immunol.
20. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothﬁeld,
J. G. Schaller, N. Talal, and R. J. Winchester. 1982. The 1982 revised criteria for
the classiﬁcation of SLE. Arthritis Rheum. 25: 1271–1277.
21. Ushmorov, A., F. Leitha¨user, O. Sakk, A. Weinhau¨sel, S. W. Popov, P. Mo¨ller,
and T Wirth. 2006. Epigenetic processes play a major role in B-cell-speciﬁc gene
silencing in classical Hodgkin lymphoma. Blood 107: 2493–2500.
22. Perl, A., J. D. Rosenblatt, I. S. Chen, J. P. DiVincenzo, R. Bever, B. J. Poiesz, and
G. N. Abraham. 1989. Detection and cloning of new HTLV-related endogenous
sequences in man. Nucleic Acids Res. 17: 6841– 6854.
23. Ruchusatsawat, K., J. Wongpiyabovorn, S. Shuangshoti, N. Hirankarn, and
A. Mutirangura. 2006. SHP-1 promoter 2 methylation in normal epithelial tissues
and demethylation in psoriasis. J. Mol. Med. 84: 175–182.
24. Jones, N. H., M. L. Clabby, D. P. Dialynas, H. J. Huang, L. A. Herzenberg, and
J. L. Strominger. 1986. Isolation of complementary DNA clones encoding the
human lymphocyte glycoprotein T1/Leu-1. Nature 323: 346 –349.
25. Reiss, D., Y. Zhang, and D. L. Mager. 2007. Widely variable endogenous ret-
roviral methylation levels in human placenta. Nucleic Acids Res. 35: 4743– 4754.
26. Hillion, S., S. Garaud, V. Devauchelle, A. Bordron, C. Berthou, P. Youinou, and
C. Jamin. 2007. IL-6 is responsible for aberrant BCR-mediated regulation of
RAG expression in SLE. Immunology 122: 371–380.
27. Robertson, K. D., K. Keyomarsi, F. A. Gonzales, M. Velicescu, and P. A. Jones.
2000. Differential mRNA expression of the human DNA methyltransferases
(DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and
tumor cells. Nucleic Acids Res. 28: 2108 –2113.
28. Brown, S. E., M. F. Fraga, I. C. Weaver, M. Berdasco, and M. Szyf. 2007.
Variations in DNA methylation patterns during the cell cycle of HeLa cells.
Epigenetics 2: 54– 65.
29. Pullmann, R., Jr., E. Bonilla, P. E. Phillips, F. A. Middleton, and A. Perl. 2008.
Haplotypes of the HRES-1 endogenous retrovirus are associated with develop-
ment and disease manifestations of systemic lupus erythematosus. Arthritis
Rheum. 58: 532–540.
30. Zhou, Y., and Q. Lu. 2008. DNA methylation in T cells from idiopathic lupus and
drug-induced lupus patients. Autoimmun. Rev. 7: 376 –383.
31. Vigorito, E., K. L. Perks, C. Abreu-Goodger, S. Bunting, Z. Xiang, S. Kohlhaas,
P. P. Das, E. A. Miska, A. Rodriguez, A. Bradley, et al. 2007. microRNA-155
regulates the generation of Ig class-switched plasma cells. Immunity 27:
32. Wang, H., J. Feng, C. F. Qi, Z. Li, H. C. Morse 3rd, and S. H. Clarke. 2007.
Transitional B cells lose their ability to receptor edit but retain their potential for
positive and negative selection. J. Immunol. 179: 7544 –7552.
33. Pang, Y., Y. Norihisa, D. Benjamin, R. R. Kantor, and H. A. Young. 1992. IFN-
gene expression in human B-cell lines: induction by IL-2, PKC, and possible
effect of hypomethylation on gene regulation. Blood 80: 724–732.
34. Huber, L. C., J. Stanczyk, A. Ju¨ngel, and S. Gay. 2007. Epigenetics in inﬂam-
matory rheumatic diseases. Arthritis Rheum. 56: 3523–3531.
35. Balada, E., J. Ordi-Ros, S. Serrano-Acedo, L. Martinez-Lostao, M. Rosa-Leyva,
and M. Vilardell-Tarre´s. 2008. Transcript levels of DNA methyltransferases
DNMT1, DNMT3A and DNMT3B in CD4⫹ T cells from patients with systemic
lupus erythematosus. Immunology 124: 339 –347.
36. Ogasawara, H., M. Okada, H. Kaneko, T. Hishikawa, I. Sekigawa, and
H. Hashimoto. 2003. Possible role of DNA hypomethylation in the induction of
SLE: relationship to the transcription of HERV. Clin. Exp. Rheumatol. 21:
37. Balada, E., J. Ordi-Ros, S. Serrano-Acedo, L. Martinez-Lostao, and
M. Vilardell-Tarre´s. 2007. Transcript overexpression of the MBD2 and MBD4
genes in CD4⫹ T cells from SLE patients. J. Leukocyte Biol. 81: 1609–1616.
38. Sawalha, A. H., M. Jeffries, R. Webb, Q. Lu, G. Gorelik, D. Ray, J. Osban,
N. Knowlton, K. Johnson, and B. Richardson. 2008. Defective T-cell ERK sig-
naling induces IFN-regulated gene expression and overexpression of methyla-
tion-sensitive genes similar to lupus patients. Genes Immun. 9: 368 –378.
39. Qiang, Y. W., M. Kitagawa, M. Higashi, G. Ishii, C. Morimoto, and K. Harigaya.
2000. Activation of MAPK through alpha5/
1 integrin is required for cell cycle
progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp.
Hematol. 28: 1147–1157.
40. Gysin, S., S. H. Lee, N. M. Dean, and M. McMahon. 2005. Pharmacologic in-
hibition of RAF–⬎MEK–⬎ERK signaling elicits pancreatic cancer cell cycle
arrest through induced expression of p27Kip1. Cancer Res. 65: 4870 –4880.
41. Richardson, B., D. Ray, and R. Yung. 2004. Murine models of lupus induced by
hypomethylated T cells. Methods Mol. Med. 102: 285–294.
42. Mi, X. B., and F. Q. Zeng. 2008. Hypomethylation of IL-4 and -6 promoters in
T cells from SLE patients. Acta Pharmacol. Sin. 29: 105–112.
5632 IL-6 CONTROLS DNA METHYLATION AND CD5 IN LUPUS B CELLS